Season 3 - Ep.12: Relevance and management of ventricular ectopic beats - Lp(a) in cardiovascular risk management

4 snips

Mar 27, 2025

Carlos Aguiar, a cardiology expert known for his contributions to 'Cardiology This Week', joins the discussion on ventricular ectopic beats and their management. He examines the significance of lipoprotein(a) in assessing cardiovascular risk, emphasizing the need for personalized monitoring. The podcast also dispels common myths about vegetarian diets and their effects on heart health, revealing mixed outcomes. Insights into treatment efficacy in heart failure and the implications of premature ventricular contractions in older patients are also highlighted.

Ask episode

AI Snips

Chapters

Transcript

Episode notes

INSIGHT

PVC Prevalence

Ventricular ectopic beats (PVCs) are common, especially in older adults.
Monitoring duration and patient age significantly influence PVC prevalence.

ADVICE

Essential PVC Investigations

For patients with frequent PVCs, assess their history and family history.
Perform Holter monitoring, echocardiography, and consider stress tests/cardiac MRI.

INSIGHT

PVC-Induced Cardiomyopathy

PVC-induced cardiomyopathy often involves high PVC burden (over 20%).
Monomorphic PVCs are typically implicated, indicated by global LV dysfunction on imaging.

Get the Snipd Podcast app to discover more snips from this episode

Get the app

This episode covers:

Cardiology This Week: A concise summary of recent studies
Relevance and management of ventricular ectopic beats
Lp(a) in cardiovascular risk management
Mythbusters: A vegetarian diet lowers cardiovascular risk

Host: Susanna Price

Guests: Carlos Aguiar, Thomas Deneke, Kausik Ray

Want to watch that episode? Go to: https://esc365.escardio.org/event/1802

Disclaimer:

ESC TV Today is supported by Bristol Myers Squibb and Novartis.

This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.

This programme is intended for health care professionals only and is to be used for educational purposes.

The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices.

Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.

Declarations of interests:

Stephan Achenbach, Thomas Deneke, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report.

Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede.

Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo.

Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.

Kausik Ray declared to have potential conflicts of interest to report: research grants from Amarin, Amgen, Daiichi Sankyo, Merck Sharp & Dohme, Pfizer, Regeneron, and Sanofi, consultant for Abbott, Amarin, Amgen, AstraZeneca, Bayer, Biologix, Boehringer Ingelheim, Cargene Therapeutics, CRISPR, CSL Behring, Eli Lilly and Company, Esperion, Kowa Pharmaceuticals, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron, Resverlogix, Sanofi, Scribe Therapeutics, Silence Therapeutics, Vaxxinity, and Viatris, honoraria for lectures from Novartis, BI, AZ, Novo Nordisk, Viatris, Amarin, Biologix Pharma, Sanofi, Amgen, Esperion, Daiichi Sankyo, Macleod and stock options New Amsterdam Pharma, Pemi 31, SCRIBE Therapeutics.

Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.